Explore new findings on bladder cancer and inflammation's role in immune suppression. Discover insights to improve treatment.

Two doses of a simple tuberculosis vaccination after surgery helps the immune system fight cancer cells and could greatly improve patient outcomes for the most common type of bladder cancer, according ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without CIS who have limited post-BCG options. Radical cystectomy remains ...

Bladder cancer is a common cancer and one of the most costly to treat, yet there has been little change in the standard of care in 40 years. This panel will focus on the unmet needs in bladder cancer ...

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...

As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...

Add Yahoo as a preferred source to see more of our stories on Google. A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...